Country: Israel
Language: English
Source: Ministry of Health
GLYCEROL PHENYLBUTYRATE
MEDISON PHARMA LTD
A16AX09
LIQUID
GLYCEROL PHENYLBUTYRATE 1.1 G / 1 ML
GASTROENTERAL, ORAL
Required
HORIZON PHARMA IRELAND LTD, IRELAND
GLYCEROL PHENYLBUTYRATE
RAVICTI is indicated for use as adjunctive therapy for chronic management of adult and paediatric patients ≥2 months of age with urea cycle disorders (UCDs) including deficiencies of carbamoyl phosphate-synthase-I (CPS), ornithine carbamoyltransferase (OTC), argininosuccinate synthetase (ASS), argininosuccinate lyase (ASL), arginase I (ARG) and ornithine translocase deficiency hyperornithinaemia-hyperammonaemia homocitrullinuria syndrome (HHH) who cannot be managed by dietary protein restriction and/or amino acid supplementation alone. RAVICTI must be used with dietary protein restriction and, in some cases, dietary supplements (e.g., essential amino acids, arginine, citrulline, protein-free calorie supplements).
2019-10-07
1 1. NAME OF THE MEDICINAL PRODUCT RAVICTI 1.1 g/ml 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml of liquid contains 1.1 g of glycerol phenylbutyrate. This corresponds to a density of 1.1 g/ml. 3. PHARMACEUTICAL FORM liquid. Clear, colourless to pale yellow liquid. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS RAVICTI is indicated for use as adjunctive therapy for chronic management of patients with urea cycle disorders (UCDs) including deficiencies of carbamoyl phosphate synthetase I (CPS), ornithine carbamoyltransferase (OTC), argininosuccinate synthetase (ASS), argininosuccinate lyase (ASL), arginase I (ARG) and ornithine translocase deficiency hyperornithinaemia-hyperammonaemia homocitrullinuria syndrome (HHH) who cannot be managed by dietary protein restriction and/or amino acid supplementation alone. RAVICTI must be used with dietary protein restriction and, in some cases, dietary supplements (e.g., essential amino acids, arginine, citrulline, protein-free calorie supplements). 4.2 POSOLOGY AND METHOD OF ADMINISTRATION RAVICTI should be prescribed by a physician experienced in the management of UCDs. Posology RAVICTI must be used with dietary protein restriction and sometimes dietary supplements (e.g., essential amino acids, arginine, citrulline, protein-free calorie supplements) depending on the daily dietary protein intake needed to promote growth and development. The daily dose should be individually adjusted according to the patient’s protein tolerance and the daily dietary protein intake needed. RAVICTI therapy may be required life long unless orthotopic liver transplantation is elected. _Adults and children _ The recommended dose for patients naïve to phenylbutyric acid and for patients switching from sodium phenylbutyrate or from sodium phenylacetate/sodium benzoate injection to RAVICTI are different. The recommended total daily dose of RAVICTI is based on body surface area and ranges from 4.5 ml/m 2 /day to 11.2 ml/m 2 /day (5.3 g/m 2 /day to 12.4 g/m 2 /day) and should take into acco Read the complete document